rs80358260
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_006432.5(NPC2):c.58G>T(p.Glu20*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00012 in 1,612,162 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000072 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00013 ( 0 hom. )
Consequence
NPC2
NM_006432.5 stop_gained
NM_006432.5 stop_gained
Scores
2
4
1
Clinical Significance
Conservation
PhyloP100: 1.08
Genes affected
NPC2 (HGNC:14537): (NPC intracellular cholesterol transporter 2) This gene encodes a protein containing a lipid recognition domain. The encoded protein may function in regulating the transport of cholesterol through the late endosomal/lysosomal system. Mutations in this gene have been associated with Niemann-Pick disease, type C2 and frontal lobe atrophy. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant located near the start codon (<100nt), not predicted to undergo nonsense mediated mRNA decay. There are 14 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 14-74493217-C-A is Pathogenic according to our data. Variant chr14-74493217-C-A is described in ClinVar as [Pathogenic]. Clinvar id is 8477.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr14-74493217-C-A is described in Lovd as [Pathogenic]. Variant chr14-74493217-C-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NPC2 | NM_006432.5 | c.58G>T | p.Glu20* | stop_gained | 1/5 | ENST00000555619.6 | NP_006423.1 | |
NPC2 | NM_001363688.1 | c.58G>T | p.Glu20* | stop_gained | 1/4 | NP_001350617.1 | ||
NPC2 | NM_001375440.1 | c.58G>T | p.Glu20* | stop_gained | 1/4 | NP_001362369.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NPC2 | ENST00000555619.6 | c.58G>T | p.Glu20* | stop_gained | 1/5 | 1 | NM_006432.5 | ENSP00000451112.2 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152188Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
11
AN:
152188
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000775 AC: 19AN: 245310Hom.: 0 AF XY: 0.0000901 AC XY: 12AN XY: 133228
GnomAD3 exomes
AF:
AC:
19
AN:
245310
Hom.:
AF XY:
AC XY:
12
AN XY:
133228
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000125 AC: 183AN: 1459974Hom.: 0 Cov.: 32 AF XY: 0.000127 AC XY: 92AN XY: 726110
GnomAD4 exome
AF:
AC:
183
AN:
1459974
Hom.:
Cov.:
32
AF XY:
AC XY:
92
AN XY:
726110
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152188Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74350
GnomAD4 genome
AF:
AC:
11
AN:
152188
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74350
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
2
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
8
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Niemann-Pick disease, type C2 Pathogenic:8Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Jan 28, 2022 | ACMG classification criteria: PVS1 very strong, PS3 supporting, PS4 strong, PM2 moderate, PM3 very strong - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 31, 2020 | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change creates a premature translational stop signal (p.Glu20*) in the NPC2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NPC2 are known to be pathogenic (PMID: 25145893). This variant is present in population databases (rs80358260, gnomAD 0.02%). This premature translational stop signal has been observed in individuals with Niemann-Pick disease type C (PMID: 11125141, 26666848). ClinVar contains an entry for this variant (Variation ID: 8477). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2007 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 30, 2022 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Mar 31, 2017 | - - |
Niemann-Pick disease, type C Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 26, 2017 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 23, 2022 | The c.58G>T (p.E20*) alteration, located in exon 1 (coding exon 1) of the NPC2 gene, consists of a G to T substitution at nucleotide position 58. This changes the amino acid from a glutamic acid (E) to a stop codon at amino acid position 20. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This alteration has been detected in the homozygous state, and in conjunction with another NPC2 disease-causing alteration, in multiple individuals with Niemann-Pick disease, type C2 (Millat, 2001; Park, 2003; Imrie, 2015; Sudrié-Arnaud, 2021). Based on the available evidence, this alteration is classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
Vest4
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at